Carboplatin vs SORAfenib

Interacting Drugs
Carboplatin Carboplatin
vs
SORAfenib
Security Level
Major, Avoid combination
Mechanism
SORAfenib: May enhance the adverse/toxic effect of CARBOplatin.
Management
Concurrent sorafenib with carboplatin and placlitaxel in patients with squamous cell lung cancer is contraindicated. Use in other settings is not specifically contraindicated but should be approached with added caution.

Subscribe for latest updates

Subscribe to our e-mail newsletter to receive updates.

No comments yet.

Post Review about Carboplatin vs SORAfenib


Other Interactions of Carboplatin

We are Developing Our database, More results coming soon.

Other Interactions of SORAfenib

We are Developing Our database, More results coming soon.